Member access

4-Traders Homepage  >  Shares  >  Copenhagen Stock Exchange  >  H. Lundbeck A/S    LUN   DK0010287234

H. LUNDBECK A/S (LUN)

36
SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo H. Lundbeck A/S
Engages in the research, development, production and sale of pharmaceuticals for the treatment of brain diseases

H. Lundbeck A/S is engaged in the research, development, production and sale of pharmaceuticals for the treatment of brain diseases.

It focuses in alcohol dependence, Alzheimer's disease, bipolar disorder, depression/anxiety, epilepsy, Huntington's disease, Parkinson's disease, schizophrenia, stroke and symptomatic neurogenic orthostatic hypotension.

The company was founded by Hans Lundbeck on August 14, and is headquartered in Valby, Denmark.

Number of employees : 5 811 persons.
Sales per Businesses
20132014Delta
DKK (in Million)%DKK (in Million)%
Cipralex5,93338.9%4,64734.5% -27.67%
Ebixa2,09613.7%1,0587.9% -98.11%
Other Pharmaceuticals1,83012%1,98514.7% +7.81%
Other Revenue1,4849.7%547.004.1% -171.3%
Xenazine1,4209.3%1,69512.6% +16.22%
Azilect1,3929.1%1,49711.1% +7.01%
Onfi573.003.8%923.006.9% +37.92%
Sabril530.003.5%716.005.3% +25.98%
Treanda--212.001.6%-
Brintellix--188.001.4%-
Sales per Regions
20132014Delta
DKK (in Million)%DKK (in Million)%
Rest of Europe7,02846.1%4,99137.1% -40.81%
Rest of the World4,07526.7%4,14430.8% +1.67%
United States2,63517.3%3,75827.9% +29.88%
Denmark36.000.2%28.000.2% -28.57%
Other Revenue--547.004.1%-
Managers
NameAgeSinceTitle
Sven Håkan Björklund MD, PhD582011Chairman
Anders Götzsche482007CFO & Executive VP-Information Technology
Anders Gersel Pedersen MD, PhD642000Executive Vice President-Research & Development
Thorleif Krarup632004Director
Jørn Møller Mayntzhusen, MBA492002Director & Senior Manager-Supply Optimisation
Christian Peter Dyvig, MBA512011Deputy Chairman
Mona Elisabeth Elster531994Director
Melanie Georgina Lee, PhD572012Independent Non-Executive Director
Lars Søren Rasmussen562013Director
Terrie Curran462014Independent Director
Shareholders
NameShares%
Lundbeck Foundation 137,351,918 69.9%
Wellington Management Co. LLP 9,866,717 5.02%
Norges Bank Investment Management 2,735,002 1.39%
OppenheimerFunds, Inc. 2,400,000 1.22%
Templeton Global Advisors Ltd. 1,748,890 0.89%
M&G Investment Management Ltd. 1,500,127 0.76%
Franklin Templeton Investment Management Ltd. 1,308,710 0.67%
Brandes Investment Partners LP 957,845 0.49%
The Vanguard Group, Inc. 851,643 0.43%
Industriens Pensionsforsikring A/S 770,102 0.39%
Sector
Healthcare
Pharmaceuticals & Medical Research
 Pharmaceuticals
  Pharmaceuticals
   Pharmaceuticals - NEC
Advertisement
Sector Pharmaceuticals
Growth (Revenue) Profitability
NOVARTIS AG
JOHNSON & JOHNSON
ROCHE HOLDING LTD..
PFIZER INC.
MERCK & CO., INC.
SANOFI
BAYER AG
NOVO NORDISK A/S
GLAXOSMITHKLINE P..
ACTAVIS PLC
BRISTOL-MYERS SQU..
ELI LILLY AND CO
ABBOTT LABORATORI..
VALEANT PHARMACEU..
TEVA PHARMACEUTIC..
SHIRE PLC
REGENERON PHARMAC..
TAKEDA PHARMACEUT..
ASTELLAS PHARMA I..
MYLAN NV
Sector Pharmaceuticals
H. Lundbeck A/S : Connections
C.P. Dyvig & Co. A/S
American Society of Clinical Oncology
International Association for the Study of Lung Cancer
Atos Medical AB
Danish Society of Medical Oncology
UNA Invest ApS
Danish Society of Internal Medicine
Fonden Lundbeck International Neuroscience Foundation
European Society for Medical Oncology
Confederation of Danish Industry
Lundbeck Cognitive Therapeutics A/S
Bisca A/S
Falck A/S
FIH Erhvervsbank A/S
Lundbeck Foundation
NightstaRx Ltd.
Danmark Amerika Fondet
The Crown Prince Frederik Fond
MT Højgaard A/S
Falck Danmark A/S
Sport ONE Danmark A/S
Company contact information
H. Lundbeck A/S
Ottiliavej 9
Valby, Capital Region 2500

Phone : +45.36.30.13.11
Fax : +45.36.30.19.40
Web : www.lundbeck.com
© 2015 People , Fundamentals and Ownership   
Dynamic quotes  
ON
| OFF